menu
    • menu

    Company profile for Strides Pharma Science

    Strides Pharma Science-PSE
    News
    Strides Names Yajuvendra Singh M R VP Of Digital Transformation

    04 Jan 2026

    // INDPHARMAPOST

    Movement in Senior Management Personnel

    03 Dec 2025

    // PRESS RELEASE

    Strides and Incepta Partner to Expand Women’s Health Access

    17 Oct 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Strides Pharma Science

    Contact Supplier

    Website

    BIO Partnering at JPM

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/7gF-7DrPhBs?si=caG7E0TfIb5WPefw

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Related CompaniesRelated Companies

    About

    Headquartered in India, Strides Pharma Science Limited is a pharmaceutical company with a major focus on the development and manufacture of IP-led niche finished dosage formulations. It is also among the world's largest manufacturers of soft gelatin capsules. With world-class manufacturing facilities, an innovative R&D hub in Bangalore and a robust commercial platform to market products globally, Strides has earned a reputation for building and scaling profitable businesses in a short span of time. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Strides Pharma Scienceindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Strides House, Bilekahalli, Bannerghatta Road, Bangalore – 560076
    Telephone
    Telephone
    +91 8067840000
    Client Email
    Email
    enquiries@synergice.co
    Client Website
    Website
    https://www.synergice.co/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/synergice/
    youtube
    YouTube
    http://www.youtube.com/@synergice
    Twitter
    Twitter
    https://x.com/strides_pharma
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/strides-pharma-science-party-content-12472.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/strides-pharma-science-party-content-3803.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Manufacturing Sites and R&D Center

    read-more

      https://www.pharmacompass.com/pdf/party/content/strides-pharma-science-party-content-28236.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2021

    read-more

      https://www.pharmacompass.com/pdf/party/content/strides-pharma-science-party-content-60913.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 14956

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Strides Names Yajuvendra Singh M R VP Of Digital Transformation
    Strides Names Yajuvendra Singh M R VP Of Digital Transformation

    04 Jan 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/people/strides-appoints-yajuvendra-singh-m-r-as-vp-digital-transformation-18763

    INDPHARMAPOST
    04 Jan 2026
    Share Share
    Movement in Senior Management Personnel
    Movement in Senior Management Personnel

    03 Dec 2025

    // PRESS RELEASE

    https://www.strides.com/Upload/PDF/strides-movement-senior-management-personnel-03122025.pdf

    PRESS RELEASE
    03 Dec 2025
    Share Share
    Strides and Incepta Partner to Expand Women’s Health Access
    Strides and Incepta Partner to Expand Women’s Health Access

    17 Oct 2025

    // PRESS RELEASE

    https://www.strides.com/Upload/PDF/strides-incepta-partner-expand-women-health-contraceptive-17102025.pdf

    PRESS RELEASE
    17 Oct 2025
    Share Share
    Strides Partners with Kenox to Expand Nasal Spray Portfolio in US
    Strides Partners with Kenox to Expand Nasal Spray Portfolio in US

    09 Sep 2025

    // PRESS RELEASE

    https://www.strides.com/Upload/PDF/StridesSEIntimation_08_sep_2025.pdf

    PRESS RELEASE
    09 Sep 2025
    Share Share
    Strides Pharma Science Report Q1 Fy26 Pat at Rs. 105.6 Cr
    Strides Pharma Science Report Q1 Fy26 Pat at Rs. 105.6 Cr

    05 Aug 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/strides-pharma-science-report-q1-fy26-pat-at-rs-1056-cr-17541

    INDPHARMAPOST
    05 Aug 2025
    Share Share
    Strides Delivers a Strong Q1FY26 with ?11,197m Revenue
    Strides Delivers a Strong Q1FY26 with ?11,197m Revenue

    29 Jul 2025

    // PRESS RELEASE

    https://www.strides.com/Upload/PDF/strides-delivers-strong-q1fy26-29072025.pdf

    PRESS RELEASE
    29 Jul 2025
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides to Market WHO-Prequalified Generic DMPA-SC in Africa

    Details:

    Medroxyprogesterone Acetate, a hormone targeting the progesterone receptor, shows promise in contraception.


    Lead Product(s): Medroxyprogesterone Acetate

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Medogen SubQ

    Study Phase: Approved FDFProduct Type: Hormone

    Recipient: Incepta Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 23, 2025

    Strides Pharma Science

    01

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Medroxyprogesterone Acetate

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Approved FDF

    Recipient : Incepta Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides to Market WHO-Prequalified Generic DMPA-SC in Africa

    Details : Medroxyprogesterone Acetate, a hormone targeting the progesterone receptor, shows promise in contraception.

    Product Name : Medogen SubQ

    Product Type : Hormone

    Upfront Cash : Inapplicable

    October 23, 2025

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides Acquires Identified ANDAs from Nostrum Laboratories, USA

    Details:

    The portfolio consists of liquids, including Nitrofurantoin, and immediate release solid orals to treat infections associated with UTIs, Pain Management, Allergy Symptoms, ADHD and Narcolepsy.


    Lead Product(s): Nitrofurantoin

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Nitrofurantoin-Generic

    Study Phase: Approved FDFProduct Type: Antibiotic

    Recipient: Nostrum Laboratories

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Acquisition May 03, 2025

    Strides Pharma Science

    02

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Nitrofurantoin

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Recipient : Nostrum Laboratories

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Strides Acquires Identified ANDAs from Nostrum Laboratories, USA

    Details : The portfolio consists of liquids, including Nitrofurantoin, and immediate release solid orals to treat infections associated with UTIs, Pain Management, Allergy Symptoms, ADHD and Narcolepsy.

    Product Name : Nitrofurantoin-Generic

    Product Type : Antibiotic

    Upfront Cash : Undisclosed

    May 03, 2025

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides Pharma receives USFDA approval for Celecoxib Capsules in multiple strengths

    Details:

    Celebrex-Generic (celecoxib) is a COX-2 inhibitor, small molecule drug candidate. It is indicated for the treatment of osteoarthritis & rheumatoid arthritis in adults.


    Lead Product(s): Celecoxib

    Therapeutic Area: Musculoskeletal Brand Name: Celebrex-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 30, 2025

    Strides Pharma Science

    03

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Celecoxib

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides Pharma receives USFDA approval for Celecoxib Capsules in multiple strengths

    Details : Celebrex-Generic (celecoxib) is a COX-2 inhibitor, small molecule drug candidate. It is indicated for the treatment of osteoarthritis & rheumatoid arthritis in adults.

    Product Name : Celebrex-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 30, 2025

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides Gains USFDA Approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg

    Details:

    The company has received approval from the US Food and Drug Administration (USFDA) for generic version for Acetaminophen and Ibuprofen tablets (250 mg/125 mg) indicated for pain and inflammation.


    Lead Product(s): Ibuprofen,Paracetamol

    Therapeutic Area: Neurology Brand Name: Advil Dual Action

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 20, 2025

    Strides Pharma Science

    04

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Ibuprofen,Paracetamol

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides Gains USFDA Approval for Acetaminophen and Ibuprofen Tablets, 125 mg /250 mg

    Details : The company has received approval from the US Food and Drug Administration (USFDA) for generic version for Acetaminophen and Ibuprofen tablets (250 mg/125 mg) indicated for pain and inflammation.

    Product Name : Advil Dual Action

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 20, 2025

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides Pharma Subsidiary Receives USFDA Approval for 60 mg Fluoxetine Tablets

    Details:

    Fluoxetine hydrochloride, is an antidepressant of the SSRIs class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, etc.


    Lead Product(s): Fluoxetine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Prozac-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 18, 2024

    Strides Pharma Science

    05

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Fluoxetine Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides Pharma Subsidiary Receives USFDA Approval for 60 mg Fluoxetine Tablets

    Details : Fluoxetine hydrochloride, is an antidepressant of the SSRIs class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, etc.

    Product Name : Prozac-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    September 18, 2024

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides Gets USFDA Nod for Theophylline Extended-Release Tablets

    Details:

    Theophylline extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.


    Lead Product(s): Theophylline

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Theo-Dur-Generic

    Study Phase: Approved FDFProduct Type: Plant Extract/Herbal

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 07, 2024

    Strides Pharma Science

    06

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Theophylline

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides Gets USFDA Nod for Theophylline Extended-Release Tablets

    Details : Theophylline extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.

    Product Name : Theo-Dur-Generic

    Product Type : Plant Extract/Herbal

    Upfront Cash : Inapplicable

    September 07, 2024

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL

    Details:

    Carafate-generic (sucralfate) is a USFDA approved pepsin A inhibitor small molecule drug candidate, which is indicated for the treatment of active duodenal ulcer.


    Lead Product(s): SucrAlphate

    Therapeutic Area: Gastroenterology Brand Name: Carafate-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 23, 2024

    Strides Pharma Science

    07

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : SucrAlphate

    Therapeutic Area : Gastroenterology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL

    Details : Carafate-generic (sucralfate) is a USFDA approved pepsin A inhibitor small molecule drug candidate, which is indicated for the treatment of active duodenal ulcer.

    Product Name : Carafate-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 23, 2024

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides Receives USFDA Approval for Sevelamer Carbonate Tablets

    Details:

    USFDA approved generic version of Sevelamer Carbonate which is used to manage elevated levels of phosphate in the blood of patients with chronic kidney disease.


    Lead Product(s): Sevelamer Hydrochloride

    Therapeutic Area: Nephrology Brand Name: Renvela-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 10, 2024

    Strides Pharma Science

    08

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Sevelamer Hydrochloride

    Therapeutic Area : Nephrology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides Receives USFDA Approval for Sevelamer Carbonate Tablets

    Details : USFDA approved generic version of Sevelamer Carbonate which is used to manage elevated levels of phosphate in the blood of patients with chronic kidney disease.

    Product Name : Renvela-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    May 10, 2024

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides Pharma Gets USFDA Nod for Antidepressant Medication

    Details:

    Fluoxetine hydrochloride (Prozac) is an SSRI antidepressant used for major depressive disorder, OCD, bulimia, and panic disorder.


    Lead Product(s): Fluoxetine Hydrochloride

    Therapeutic Area: Psychiatry/Psychology Brand Name: Prozac-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 08, 2024

    Strides Pharma Science

    09

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Fluoxetine Hydrochloride

    Therapeutic Area : Psychiatry/Psychology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides Pharma Gets USFDA Nod for Antidepressant Medication

    Details : Fluoxetine hydrochloride (Prozac) is an SSRI antidepressant used for major depressive disorder, OCD, bulimia, and panic disorder.

    Product Name : Prozac-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    April 08, 2024

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Strides Receives USFDA Approval for Gabapentin Tablets USP, 600 mg and 800 mg

    Details:

    USFDA approved generic version of Gabapentin tablet, which is an anticonvulsant medication primarily used to treat partial seizures and neuropathic pain.


    Lead Product(s): Gabapentin

    Therapeutic Area: Neurology Brand Name: Neurontin-Generic

    Study Phase: Approved FDFProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 05, 2024

    Strides Pharma Science

    10

    Strides Pharma Science

    India
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSynergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.

    Lead Product(s) : Gabapentin

    Therapeutic Area : Neurology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Strides Receives USFDA Approval for Gabapentin Tablets USP, 600 mg and 800 mg

    Details : USFDA approved generic version of Gabapentin tablet, which is an anticonvulsant medication primarily used to treat partial seizures and neuropathic pain.

    Product Name : Neurontin-Generic

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 05, 2024

    Strides Pharma Science

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search